2009 Global Initiative for Chronic Obstructive Lung Disease (GOLD)

Program Description:

National Guidelines Update: The New COPD GOLD Guidelines 2009 is a certified, 60-minute news style program which reviews the 2009 update to the guidelines for the management of COPD produced by the Global Initiative for Obstructive Lung Disease (GOLD).

The program begins with a brief overview of COPD and treatment options as outlined in the GOLD guidelines. Our faculty, Dr. Fernando Martinez (member of the GOLD executive committee) puts the guidelines into clinical perspective by describing the every day application of key points from the guidelines. This is followed by a lively interview and discussion between our program chair, Dr. Neil Skolnik (Professor of Family and Community Medicine at Temple University School of Medicine) and Dr. Martinez. During this clinical exchange, Dr. Skolnik and Dr. Martinez discuss controversies and areas of debate in the management of patients with COPD. Dr. Martinez gives advice on how to manage patients that fall into “gray areas” and addresses “frequently asked questions”.

This educational activity is multi-supported by educational grants from AstraZeneca and Boehringer Ingelheim.

Activity Objectives:

After participating in this activity, clinicians should be better able to:

• Describe the approach to the diagnosis of COPD


• Assess and monitor COPD


• Describe the management of COPD


• Give recommendations for reducing risk factors for COPD


• Describe the evidence base for recommendations made in the COPD GOLD guidelines


• Describe “what’s new” in the 2009 COPD GOLD guidelines


• Be motivated to translate the COPD GOLD guidelines into clinical practice

Faculty:

Neil Skolnik, MD (program chair)
Professor of Family and Community Medicine
Temple University School of Medicine
Associate Director, Family Medicine Residency Program
Abington Memorial Hospital
Abington, PA

Fernando Martinez, MD, MS
Professor of Internal Medicine
Director of Pulmonary Diagnostic Services
A. Alfred Taubman Health Center, University of Michigan, Ann Arbor
Ann Arbor, MI

Disclosures:

It is the policy of Temple University School of Medicine, The Albert J. Finestone, M.D. Office for Continuing Medical Education to insure balance, independence, objectivity and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).

The information presented on this web portal represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

The planning committee of this program has no relevant relationships to disclose.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Neil Skolnik, MD is a consultant for AstraZeneca, Takeda Pharmaceuticals, and Schering-Plough/Merck and is on the speaker’s bureau for AstraZeneca.

Fernando Martinez, MD has received grant/research support from Actelion, Glaxo Smith Kline, and Nycomed. He is also a consultant to Actelion, Almirall, AstraZeneca, Boehringer Ingelheim, Bayer, Elan, Gilead, GlaxoSmithKline, Johnson & Johnson, Novartis, Nycomed/Forest, Schering Plough, and United Bio Source. Dr. Fernando is also on the speaker’s bureau for AstraZeneca, Boehringer Ingelheim, France Foundation, GlaxoSmithKline, NACE, and Potomac Center for Medical Education. He is also on the GOLD Steering and Science Committees.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Temple University School of Medicine do not recommend the use of any agent outside of the labeled indications.

The views and opinions expressed herein are those of the authors and do not necessarily represent those of Temple University School of Medicine or National Guidelines Update.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH^® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.